Patient Profiles

Quillivant XR enables healthcare professionals to fine-tune the dose* and significantly improve attention and behavior from morning through homework time.

  • 8 years old, 3rd grade
  • Currently taking a long-acting stimulant in pill form
  • Does not want to swallow a pill
  • Parents appreciate that the healthcare professional can fine-tune the dose and significantly improve their child's attention and behavior from morning through homework time

  • 6 years old, 1st grade
  • Recently diagnosed with ADHD
  • Has never swallowed a pill but has taken liquid medications in the past
  • Caregiver is looking for different formulation options that may help to balance efficacy and side effects

*Prior to treating pediatric patients and adults with CNS stimulants, including Quillivant XR, assess for the presence of cardiac disease (ie, perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam). Starting dose is 20 mg, which can be titrated up or down, weekly, in increments of 10 to 20 mg up to a maximum dose of 60 mg. Reduce dosage if a paradoxical aggravation of symptoms or other adverse events occur. Discontinue if intolerable side effects develop or after 1 month of improvement is not seen after appropriate dose adjustments.

QuilliChew ER offers multiple dosage strengths with scored tablet options, which enable healthcare professionals to individualize the dose* to meet the specific treatment needs of patients with ADHD.

  • 12 years old, 7th grade
  • Currently taking a liquid long-acting medication for ADHD
  • Sarah and her caregiver have discussed alternate treatment formulations with her healthcare professional
  • Has taken a chewable medication in the past

  • 9 years old, 4th grade
  • Recently diagnosed with ADHD
  • Parents value the flexibility QuilliChew ER offers with multiple dosage strengths
  • Has never swallowed a pill but has taken chewable medications in the past
  • Parents and patient prefer a chewable tablet

*Prior to treating pediatric patients and adults with CNS stimulants, including QuilliChew ER, assess for the presence of cardiac disease (ie, perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam). The recommended starting dose is 20 mg given orally once daily in the morning. Dosage may be increased or decreased weekly in increments of 10 mg, 15 mg, or 20 mg per day. Daily dosage above 60 mg is not recommended. Reduce dosage or discontinue therapy if patients exhibit paradoxical aggravation of symptoms or other side effects, or if improvement is not observed after an appropriate dose adjustment over a 1-month period.